BRPI0108882B8 - combinação farmacêutica - Google Patents
combinação farmacêuticaInfo
- Publication number
- BRPI0108882B8 BRPI0108882B8 BRPI0108882A BR0108882A BRPI0108882B8 BR PI0108882 B8 BRPI0108882 B8 BR PI0108882B8 BR PI0108882 A BRPI0108882 A BR PI0108882A BR 0108882 A BR0108882 A BR 0108882A BR PI0108882 B8 BRPI0108882 B8 BR PI0108882B8
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- pharmaceutical
- pharmaceutical combination
- organs
- blood supply
- Prior art date
Links
- 210000000056 organ Anatomy 0.000 abstract 3
- 230000036770 blood supply Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 abstract 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract 1
- 206010021138 Hypovolaemic shock Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000004221 Multiple Trauma Diseases 0.000 abstract 1
- 206010051606 Necrotising colitis Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 101710142969 Somatoliberin Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 abstract 1
- 230000008816 organ damage Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 206010040560 shock Diseases 0.000 abstract 1
- 238000011477 surgical intervention Methods 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"combinação farmacêutica, composição farmacêutica, e, uso da dita combinação". a presente invenção diz respeito à medicina humana e, em particular, a uma combinação farmacêutica do fator de crescimento epidérmico (egf) com um peptídeo mimético do fator de liberação do hormônio do crescimento (ghrp), que é útil na prevenção e/ou restauração da lesão tecidual causada pela irrigação sangüínea deficiente de um órgão determinado, devida a diferentes condições patológicas. a mencionada combinação pode ser usada dentro da mesma composição farmacêutica ou aplicada separadamente a um mesmo paciente como parte de um tratamento único que favoreça a vitalidade celular nos órgãos quando estes sejam submetidos a perda parcial ou total no suprimento de sangue oxigenado durante um período de tempo. esta combinação também atenua a formação de espécies tóxicas e metabólitos nos referidos órgãos, o que é particularmente útil aos tecidos submetidos a prolongados períodos de isquemia. a combinação farmacêutica pode ser aplicada, além disso, para fins profiláticos, a pacientes com condições que possam conduzir à disfunção ou lesão múltipla de órgãos de várias origens, como queimaduras, politraumatismos, síndrome da angústia respiratória, neonatos hipóxicos, choque hipovolêmico, enterocolite necrotizante, assim como a pacientes submetidos a grandes intervenções cirúrgicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20010005A CU23157A1 (es) | 2001-01-03 | 2001-01-03 | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
| PCT/CU2001/000013 WO2002053167A2 (es) | 2001-01-03 | 2001-12-17 | Combinacion farmaceutica para el tratamiento del dano tisular debido a falta de irrigacion sanguinea arterial |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0108882A BR0108882A (pt) | 2003-04-29 |
| BRPI0108882B1 BRPI0108882B1 (pt) | 2016-06-14 |
| BRPI0108882B8 true BRPI0108882B8 (pt) | 2021-05-25 |
Family
ID=40091523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0108882A BRPI0108882B8 (pt) | 2001-01-03 | 2001-12-17 | combinação farmacêutica |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7361638B2 (pt) |
| EP (1) | EP1354597B1 (pt) |
| JP (2) | JP4181875B2 (pt) |
| KR (1) | KR100839857B1 (pt) |
| CN (1) | CN1247256C (pt) |
| AR (1) | AR032217A1 (pt) |
| AT (1) | ATE302017T1 (pt) |
| AU (1) | AU2002216897A1 (pt) |
| BR (1) | BRPI0108882B8 (pt) |
| CA (2) | CA2398983C (pt) |
| CU (1) | CU23157A1 (pt) |
| DE (1) | DE60112807T2 (pt) |
| DK (1) | DK1354597T3 (pt) |
| EA (2) | EA007466B1 (pt) |
| ES (1) | ES2248229T3 (pt) |
| MX (1) | MXPA02008667A (pt) |
| MY (1) | MY129079A (pt) |
| SI (1) | SI1354597T1 (pt) |
| WO (1) | WO2002053167A2 (pt) |
| ZA (1) | ZA200206954B (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060128615A1 (en) * | 2002-09-18 | 2006-06-15 | Pierrette Gaudreau | Ghrh analogues |
| EP1684786A4 (en) * | 2003-10-24 | 2007-12-12 | Merck & Co Inc | IMPROVING THE MIRROR OF THE GROWTH HORMONE WITH A DIPEPTIDYL PEPTIDASE IV INHIBITOR AND A GROWTH HORMONE SECRETAGOG |
| EP1529533A1 (en) * | 2003-11-06 | 2005-05-11 | Sahltech I Göteborg AB | Use of GH secretagogues in hypoxic-ischemic brain injury |
| WO2005058345A1 (en) * | 2003-12-16 | 2005-06-30 | University Technologies International Inc. | A treatment for necrotizing enterocolitis |
| CU23529A1 (es) * | 2005-03-02 | 2010-06-17 | Ct Ingenieria Genetica Biotech | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
| CU23389B6 (es) * | 2005-12-29 | 2009-07-16 | Ct Ingenieria Genetica Biotech | Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica |
| CU23592A1 (es) * | 2006-02-28 | 2010-11-11 | Ct Ingenieria Genetica Biotech | Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6 |
| CU23526B6 (es) | 2006-10-03 | 2010-05-19 | Ct Ingenieria Genetica Biotech | Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética |
| PL2118123T3 (pl) | 2007-01-31 | 2016-06-30 | Dana Farber Cancer Inst Inc | Stabilizowane peptydy p53 i ich zastosowania |
| RU2328288C1 (ru) * | 2007-02-21 | 2008-07-10 | ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Способ лечения трофических язв нижних конечностей при посттромботической болезни |
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| US8093213B2 (en) * | 2007-04-30 | 2012-01-10 | Nationwide Children's Hospital, Inc. | Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation |
| US20110166068A1 (en) | 2008-07-17 | 2011-07-07 | Acorda Therapeutics, Inc. | Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure |
| KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| EP2768518A4 (en) | 2011-10-18 | 2015-05-27 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES |
| RU2642299C2 (ru) | 2012-02-15 | 2018-01-24 | Эйлерон Терапьютикс, Инк. | P53 пептидомиметические макроциклы |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| WO2014152906A2 (en) | 2013-03-14 | 2014-09-25 | Research Institute At Nationwide Children's Hospital, Inc. | Tissue engineered intestine |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| EP3197478A4 (en) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP2018516844A (ja) | 2015-03-20 | 2018-06-28 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその使用 |
| KR102733066B1 (ko) | 2015-06-26 | 2024-11-21 | 주식회사 파마리서치 | 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물 |
| US11197944B2 (en) | 2015-11-18 | 2021-12-14 | President And Fellows Of Harvard College | Compositions and methods of mechanically inducing tissue regeneration |
| CU24591B1 (es) * | 2018-08-21 | 2022-04-07 | Ct Ingenieria Genetica Biotecnologia | Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento |
| US11564975B2 (en) | 2018-08-21 | 2023-01-31 | Centro De Ingeniería Genética Y Biotecnología | Use of GHRP-6 as late cardioprotective and cardiac restoration medicament |
| CN109908331A (zh) * | 2019-04-30 | 2019-06-21 | 青岛大学附属医院 | 海沙瑞林在制备保护肾脏缺血再灌注损伤药物/药物组合物中的应用 |
| WO2025242247A1 (es) | 2024-05-21 | 2025-11-27 | Centro De Ingeniería Genética Y Biotecnología | Uso del péptido ghrp-6 para el tratamiento de la senescencia y la cicatrización de heridas crónicas complejas refractarias |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057494A (en) | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
| US5360790A (en) * | 1990-12-11 | 1994-11-01 | The Regents Of The University Of Michigan | Method and formulations for the therapy of acute renal failure |
| KR970032600A (ko) | 1995-12-30 | 1997-07-22 | 배순훈 | 전기압력보온밥솥용 압력센싱장치의 이상 발생인식방법 |
| SE9703929D0 (sv) | 1996-11-22 | 1997-10-28 | Pharmacia & Upjohn Ab | Therapeutical use and method |
| KR100226985B1 (ko) * | 1997-07-14 | 1999-10-15 | 윤재승 | 신규한 인간성장호르몬방출인자-인간상피세포성장인자 융합유전자, 이의 발현벡터 및 이를 이용한 인간성장호르몬방출인자의 제조방법 |
| US6191109B1 (en) * | 1997-10-31 | 2001-02-20 | Children's Hospital, Inc. | Methods of treating intestinal ischemia using heparin-binding epidermal growth factor |
| US6124263A (en) * | 1998-11-16 | 2000-09-26 | Asta Medica Ag | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| AU6133299A (en) | 1998-09-02 | 2000-03-21 | Merck & Co., Inc. | Enhancement of return to independent living status with a growth hormone secretagogue |
| US6194578B1 (en) | 1998-11-20 | 2001-02-27 | Pfizer Inc. | Dipeptide derivatives |
| JP2004507456A (ja) * | 2000-05-11 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体 |
| US20020061838A1 (en) | 2000-05-17 | 2002-05-23 | Barton Holmquist | Peptide pharmaceutical formulations |
| ES2292900T3 (es) * | 2000-06-13 | 2008-03-16 | Aeterna Zentaris Gmbh | Secretagogos de la hormona del crecimiento. |
-
2001
- 2001-01-03 CU CU20010005A patent/CU23157A1/es unknown
- 2001-12-17 DK DK01272599T patent/DK1354597T3/da active
- 2001-12-17 KR KR1020027011276A patent/KR100839857B1/ko not_active Expired - Fee Related
- 2001-12-17 WO PCT/CU2001/000013 patent/WO2002053167A2/es not_active Ceased
- 2001-12-17 AU AU2002216897A patent/AU2002216897A1/en not_active Abandoned
- 2001-12-17 JP JP2002554116A patent/JP4181875B2/ja not_active Expired - Fee Related
- 2001-12-17 ES ES01272599T patent/ES2248229T3/es not_active Expired - Lifetime
- 2001-12-17 CN CNB018059783A patent/CN1247256C/zh not_active Expired - Lifetime
- 2001-12-17 EP EP01272599A patent/EP1354597B1/en not_active Expired - Lifetime
- 2001-12-17 SI SI200130436T patent/SI1354597T1/sl unknown
- 2001-12-17 DE DE60112807T patent/DE60112807T2/de not_active Expired - Lifetime
- 2001-12-17 EA EA200500646A patent/EA007466B1/ru not_active IP Right Cessation
- 2001-12-17 MX MXPA02008667A patent/MXPA02008667A/es active IP Right Grant
- 2001-12-17 EA EA200200850A patent/EA006036B1/ru not_active IP Right Cessation
- 2001-12-17 BR BRPI0108882A patent/BRPI0108882B8/pt not_active IP Right Cessation
- 2001-12-17 CA CA2398983A patent/CA2398983C/en not_active Expired - Lifetime
- 2001-12-17 US US10/220,750 patent/US7361638B2/en not_active Expired - Lifetime
- 2001-12-17 CA CA 2789161 patent/CA2789161C/en not_active Expired - Lifetime
- 2001-12-17 AT AT01272599T patent/ATE302017T1/de active
- 2001-12-19 MY MYPI20015758A patent/MY129079A/en unknown
- 2001-12-28 AR ARP010106097A patent/AR032217A1/es unknown
-
2002
- 2002-08-29 ZA ZA200206954A patent/ZA200206954B/en unknown
-
2008
- 2008-05-30 JP JP2008141792A patent/JP4958844B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0108882A (pt) | Combinação farmacêutica, composição farmacêutica, e, uso da dita combinação | |
| Zhu et al. | Remote preconditioning, perconditioning, and postconditioning: a comparative study of their cardioprotective properties in rat models | |
| Ramsey et al. | Immediate open reduction and internal fixation of severely displaced supracondylar fractures of the humerus in children | |
| Alworth et al. | Laboratory reptile surgery: principles and techniques | |
| Wilkman et al. | The free scapular flap with latissimus muscle reduces fistulas in mandibular reconstruction | |
| Fleming | Clinical technique: chelonian shell repair | |
| Lew et al. | Laparoscopic cryptorchidectomy in dogs--report of 15 cases | |
| Marini et al. | Anesthesia and select surgical procedures | |
| Kanai et al. | Video-assisted thoracic surgery anatomical lobectomy for a primary lung tumor in a dog | |
| Parmentier et al. | Intubation, central venous catheter, and arterial line placement in swine for translational research in abdominal transplantation surgery | |
| White et al. | Left principal bronchus rupture in a cat | |
| Swindle et al. | Surgery: Basic Principles and Procedures | |
| Liptak et al. | Surgery of the thoracic wall | |
| Barone et al. | Blood-flow measurements of injured peripheral nerves by laser Doppler flowmetry | |
| Duke et al. | Cardiopulmonary effects associated with head–down position in halothane–anesthetized ponies with or without capnoperitoneum | |
| Bennett et al. | Surgical management of bifid sternum in two African grey parrots | |
| RU2789004C1 (ru) | Способ повышения уровня сознания пациентов с длительным нарушением сознания после черепно-мозговой травмы | |
| Sinhorelli et al. | Elective laparoscopic ovariectomy in domestic swine (Sus scrofa domesticus) | |
| LAVANYA et al. | ASSESSMENT OF TOTAL INTRAVENOUS ANESTHESIA BY PROPOFOL AND INHALATIONAL ANESTHESIA WITH ISOFLURANE FOR CONTROLLED HYPOTENSION IN FUNCTIONAL ENDOSCOPIC SINUS SURGERY | |
| Dsouza et al. | Anaesthetic management of a patient with multiple system atrophy | |
| Vergneau‐Grosset et al. | Amphibian Surgery | |
| Shamsiev et al. | Results of surgical treatment of lymphangiomas in children | |
| SINGH et al. | TEN YEARS RETROSPECTIVE AUTOPSY STUDY OF THROTTLING AND TRAUMATIC ASPHYXIA | |
| Lechiancole et al. | Sternette®: An Alternative Closure Device after Median Sternotomy | |
| Lal et al. | Gartland Type Iii Supracondylar Fracture Humerus: Surgical Management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/06/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |
|
| B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2703 DE 25/10/2022 POR TER SIDO INDEVIDA, UMA VEZ QUE A VALIDADE DA PATENTE FOI ATE 17/12/2021. |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 17/12/2021 |